Sage Therapeutics, Inc.

Sage Therapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Sage Therapeutics, Inc. is not a good value stock. Sage Therapeutics, Inc. is not a good growth stock. Sage Therapeutics, Inc. is not very popular among insiders. Sage Therapeutics, Inc. is a mediocre stock to choose.
Log in to see more information.
SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the d...
SAGE Fundamental Data by TradingView

News

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc. (SAGE) Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc. (SAGE) Investors

Business Wire Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Sage Therapeutics, Inc. (Sage or the Company) (NASDAQ: SAGE) securities...\n more…

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc. (SAGE) Investors
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc. (SAGE) Investors

Business Wire The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Sage Therapeutics, Inc. (Sage or the...\n more…

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Sage Therapeutics, Inc. (SAGE) on Behalf of Investors
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Sage Therapeutics, Inc. (SAGE) on Behalf of Investors

Business Wire Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sage Therapeutics, Inc. (Sage or the Company...\n more…

Sage Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE
Sage Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE

PR Newswire Sage Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE Sage...\n more…

Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $16.06 Average PT from Brokerages
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $16.06 Average PT from Brokerages

Zolmax Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has been assigned a consensus recommendation of "Reduce" from the nineteen research firms that are currently covering the company...\n more…

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Sage Therapeutics, Inc. (SAGE) on Behalf of Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Sage Therapeutics, Inc. (SAGE) on Behalf of Investors

Business Wire Law Offices of Howard G. Smith announces an investigation on behalf of Sage Therapeutics, Inc. (Sage or the Company) (NASDAQ: SAGE) investors concerning the Companys possible violations of federal...\n more…